-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Skin Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Skin Cancer Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pamiparib in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pamiparib in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pamiparib in Small-Cell Lung Cancer Drug Details: Pamiparib is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-253 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-253 in Refractory Acute Myeloid Leukemia Drug Details: KT-253...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-253 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-253 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-253 in Relapsed Acute Myeloid Leukemia Drug Details: KT-253...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talimogene Laherparepvec in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talimogene Laherparepvec in Metastatic Renal Cell Carcinoma Drug...
-
Product Insights
NewNet Present Value Model: Kymera Therapeutics Inc’s KT-253
Empower your strategies with our Net Present Value Model: Kymera Therapeutics Inc's KT-253 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-333 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-333 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: KT-333...
-
Product Insights
NewNet Present Value Model: Kymera Therapeutics Inc’s KT-333
Empower your strategies with our Net Present Value Model: Kymera Therapeutics Inc's KT-333 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Sumitomo Pharma Co Ltd’s Ulotaront
Empower your strategies with our Net Present Value Model: Sumitomo Pharma Co Ltd's Ulotaront report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-333 in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-333 in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-333 in Cutaneous T-Cell Lymphoma Drug Details: KT-333 is under...